Sting Therapeutics

Sting Therapeutics is a Singapore-based biotechnology company dedicated to advancing cancer immunotherapy through the modulation of the STING (Stimulator of Interferon Genes) pathway. The company is developing a pipeline of novel, small-molecule STING agonists designed to overcome the pharmacological hurdles of earlier-generation candidates, such as poor bioavailability and rapid clearance. By selectively activating the innate immune system within the tumor microenvironment, Sting Therapeutics aims to turn cold tumors hot and improve outcomes for patients with various solid tumors. Their approach leverages deep expertise in immunology and medicinal chemistry to create systemic and intratumoral therapies.